Enfermedad pulmonar intersticial asociada a esclerosis sistémica (EPI-ES)

 

Associations between extent of fibrotic interstitial lung disease (ILD) and forced vital capacity (FVC) at baseline and change in FVC in subjects with systemic sclerosis-associated ILD (SSc-ILD) in the SENSCIS trial

Denton CP et al.
 

Acceder

Effect of nintedanib on decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) by GAP stage and ILD-GAP index

Kreuter M et al.

 

Acceder

Decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) with and without cough: data from the SENSCIS trial

Kreuter M et al.

 

Acceder

 

 

Impact of forced vital capacity decline on hospitalization events in systemic sclerosis-associated interstitial lung disease: a joint model analysis using data from the SENSCIS trial

Kreuter M et al.
 

Acceder

Correlations between changes in FVC and imaging parameters in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD): sub-study of the SENSCIS trial

Humphries SM et al.
 

Acceder

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): data from the SENSCIS-ON trial

Highland KB et al.

 

Acceder